Benefits and risks of pharmacotherapy for dysthymia: A systematic appraisal of the evidence

Drug Safety

Volumn 26, Issue 1, 2003, Pages 55-64

  De Lima, Maurício S ^a,b   Hotopf, Matthew ^c  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINEPTINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; FLUOXETINE; FLUPENTIXOL; IMIPRAMINE; MINAPRINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VILOXAZINE;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSTHYMIA; EMBASE; HUMAN; MEDLINE; PRIORITY JOURNAL; PSYCINFO; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DIBENZOCYCLOHEPTENES; DYSTHYMIC DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RITANSERIN; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE; TREATMENT OUTCOME;

EID: 0037225247     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326010-00006     Document Type: Article

References (44)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III). 3rd ed. Washington, DC: American Psychiatric Association, 1980
2. Weissman MM, Leaf PJ, Bruce ML, et al. The epidemiology of dysthymia in five communities: rates, risks, comorbidity and treatment. Am J Psychiatry 1988; 145 (7): 815-9
3. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiatry 1983; 140: 11-20
4. Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996; 53: 777-84
5. WPA Dysthymia Working Group. Dysthymia in clinical practice. Br J Psychiatry 1995; 166: 174-83
6. Kocsis JH. Chronic depression: the efficacy of pharmacotherapy. In: Akiskal HS, Cassano GB, editors. Dysthymia and the spectrum of chronic depression. New York: The Guilford Press, 1997
7. Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 1998
8. Lima MS, Hotopf M, Wessely S. The efficacy of drug treatments for dysthymia. Psychol Med 1999; 29 (6): 1273-89
9. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12
10. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-12
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987
12. Stewart JW, McGrath PJ, Liebowitz MR, et al. Treatment outcome validation of DSM-III depressive subtypes: clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985; 42: 1148-53
13. Reyntjens A, Gelders YG, Hoppenbrouwers MLJA, et al. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 1986; 8: 205-11
14. Kocsis JH, Frances AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988; 45: 253-7
15. Stewart JW, McGrath PJ, Quitkin FM, et al. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 1989; 46: 1080-7
16. Botte L, Evrard JL, Gilles C, et al. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression. Acta Psychiatr Belg 1992; 92: 355-69
17. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990; 10: 355-60
18. Costa e Silva J. Traitement des dysthymies par de faibles doses d'amisulpride. Etude comparative amisulpride 50 mg/j versus placebo. Annales De Psychiatrie 1990; 5 (3): 242-9
19. Bersani G, Pozzi F, Marini S, et al. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83: 244-8
20. Bakish D, Lapierre YD, Weinstein R, et al. Ritanserin, imipramine and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993; 13 (6): 409-14
21. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993; 150: 1169-75
22. Boyer P, Lecrubier Y. Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine. Eur Psychiatry 1996; 11 Suppl. 3: 135S-40S
23. Ravindran AV, Guelfi JD, Lane RM, et al. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 2000; 61 (11): 821-7
24. Reyntjens A, Gelders YG, Hoppenbrouwers MLJA, et al. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 1986; 8: 205-11
25. Vanelle JM. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 1997; 170: 345-50
26. Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. Int Clin Psychopharmacol 1997; 12: 183-93
27. Williams Jr JW, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000; 284 (12): 1519-26
28. Kocsis JH, Sutton BM, Frances AJ. Long-term follow-up of chronic depression treated with imipramine. J Clin Psychiatry 1991; 52: 56-9
29. Kocsis JH, Friedman RA, Markowitz JC, et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996; 53: 769-74
30. Harrison W, Rabkin J, Stewart JW, et al. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986; 47: 346-9
31. Otero FJ, Hernandez-Herrero C, Martinez-Arevalo M-J, et al. Fluoxetine/bentazepam combination in the treatment of dysthymic disorders. Curr Ther Res 1994; 55 (5): 519-31
32. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. Long-term treatment of double depression: a preliminary study with serotonergic antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 139-47
33. Geisler A, Mygind S, Knudsen R, et al. Ritanserin and flupenthixol in dysthymic disorder. Nord J Psychiatry 1992; 46: 237-43
34. Guelfi JD, Pichot P, Dreyfus JF. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptiline. Neuropsychobiology 1989; 22: 41-8
35. Leon CA, Vigoya J, Conde S, et al. Comparacion del efecto de la amisulprida y la viloxacina en el tratamiento de la distimia (Therapeutic efficacy of amisulpride and viloxazine in the treatment of dysthymia: a comparison). Acta Psiquiatr Psicol Am Lat 1994; 40 (1): 41-9
36. Rosenthal J, Hemlock C, Hellerstein DJ, et al. A preliminary study of serotonergic antidepressants in treatment of dsythymia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 933-41
37. Salzmann E, Robin JL. Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders. Neuropsychobiology 1995; 31: 68-75
38. Smeraldi E, Haefele E, Crespi G, et al. Amisulpride versus fluoxetine in dysthymia: preliminary results of a double-blind comparative study. Eur Psychiatry 1996; 11 Suppl. 3: 141S-3S
39. Vallejo J, Gastro C, Catalan R, et al. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987; 151: 639-42
40. Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002
41. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002
42. Kapczinski F, Schmitt R, Lima MS. The use of antidepressants for generalized anxiety disorder. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002
43. Mulrow CD, Williams Jr JW, Trivedi M, et al. Treatment of depression: newer pharmacotherapies: evidence report/technology assesment no. 7. Prepared by the San Antonio Evidence-based Practice Center based at The University of Texas Health Science Center at San Antonio under Contract 290-97-0012
44. Barbui C, Hotopf M, Freemantle N, et al. Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2002